Big Pharma Has Eye On Pharmacopeia’s DARA For Blood Pressure
This article was originally published in The Pink Sheet Daily
Executive Summary
DARA, a first-in-class dual-acting angiotensin and endothelin receptor antagonist in development for hypertension and diabetic nephropathy, is in Phase II development.